Site Editor

Sandy Srinivas, MD

Advertisement

Advertisement

News

RALU Study: Impact of Sequencing Radionuclide Therapies on Outcomes in Prostate Cancer

News

Second-Generation AR Inhibitors in Prostate Cancer: Findings From the Real-World DEAR Trial

News

Final Overall Survival Data From PROpel on Abiraterone Plus Olaparib in Metastatic Prostate Cancer

Medical Literature

More MAGNITUDE Results in Prostate Cancer With Niraparib for Additional HRR Alterations

Medical Literature

VA Study Addresses the Impact of PSA Screening on Subsequent Metastatic Prostate Cancer

News

ASCO GU 2023: Use of Darolutamide in a Racially Diverse Patient Population With Metastatic Prostate Cancer

News

Study Finds Skin Color Seems to Matter in Prostate Cancer Treatment Offerings

Tanya Dorff, MD, on New Findings on Talazoparib Monotherapy in Prostate Cancer

Neal D. Shore, MD, on New Data on the Safety and Efficacy of Darolutamide in Patients With Prostate Cancer

View More

Advertisement

JNCCN Spotlights

Lutetium Lu-177 Vipivotide Tetraxetan

(UPDATE September 2022) Enzalutamide

(UPDATE) Degarelix (Injectable GnRH Antagonist)

Docetaxel (Castration-Naive Metastatic Prostate Cancer)

UPDATE October 2020 Enzalutamide

Degarelix (Injectable GnRH Antagonist)

(UPDATE) Apalutamide in Prostate Cancer

View More

More

News

Recruitment Opens for PRESERVE Trial: Focal Therapy May Be Alternative to Surgery

ASCO GU 2023: Nivolumab Plus Ipilimumab After Chemotherapy for Resistant Prostate Cancer

ASCO GU 2023: Adding Hormone Therapy Plus an Antiandrogen to Salvage Therapy for High-Risk Prostate Cancer

Can Lymph Node Degeneration Impact Metastasis of Prostate Cancer?

SAKK 08/16 Results Show Benefit of Darolutamide Maintenance in Metastatic Prostate Cancer

AR Inhibitor Plus Androgen-Deprivation Therapy in Prostate Cancer: ARASENS Update on Disease Volume and Risk

ASCO GU 2023: PSA Response to Darolutamide Monotherapy in Hormone-Naive Prostate Cancer

RALU Study: Impact of Sequencing Radionuclide Therapies on Outcomes in Prostate Cancer

View More

Advertisement

Published

Medical Literature

Researchers Offer Evidence That Prostate Cancer Biology May Differ by Racial Ancestry

Adding Darolutamide to Standard Treatment in Metastatic, Hormone-Sensitive Prostate Cancer

Enzalutamide Monotherapy: Active Surveillance Alternative in Low- or Intermediate-Risk Prostate Cancer?

Can the Number of Positive Pelvic Lymph Nodes Guide Adjuvant Radiation Therapy for Prostate Cancer?

View More

Ongoing

CE Activities

Genitourinary Cancers: Assessing the Roles of Immune-Based and Targeted Therapies in a Changing Treatment Landscape

Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2022 ASCO Annual Meeting

Talk to Someone: Explore Talking to Patients About Prostate Cancer Treatment

Patient Simulations in Personalized Planning for Prostate Cancer

View More

Available

Clinical Trials

University of Nebraska

Seidman Cancer Center

City of Hope

Dana-Farber Cancer Institute

View More

Resources

For Your Patients

Prostate Health Education Network

Urology Care Foundation

Cancer Support Community

Prostate Cancer Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.